Windtree Therapeutics Inc (WINT) - Total Liabilities
Based on the latest financial reports, Windtree Therapeutics Inc (WINT) has total liabilities worth $27.58 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Windtree Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Windtree Therapeutics Inc - Total Liabilities Trend (1995–2024)
This chart illustrates how Windtree Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Windtree Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Windtree Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Faron Pharmaceuticals Oy
LSE:FARN
|
UK | GBX32.45 Million |
|
Town Centre Securities PLC
LSE:TOWN
|
UK | GBX188.89 Million |
|
Oxbridge Re Holdings Equity Warrant
NASDAQ:OXBRW
|
USA | $1.56 Million |
|
MEDICOX Co. Ltd
KQ:054180
|
Korea | ₩27.34 Billion |
|
Ireka Corporation Bhd
KLSE:8834
|
Malaysia | RM268.86 Million |
|
R.E.A. Holdings plc
LSE:RE
|
UK | GBX277.65 Million |
|
Naked Wines plc
LSE:WINE
|
UK | GBX107.52 Million |
|
Ecoclime Group AB Series B
ST:ECC-B
|
Sweden | Skr12.46 Million |
Liability Composition Analysis (1995–2024)
This chart breaks down Windtree Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see WINT stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Windtree Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Windtree Therapeutics Inc (1995–2024)
The table below shows the annual total liabilities of Windtree Therapeutics Inc from 1995 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $17.88 Million | -38.38% |
| 2023-12-31 | $29.02 Million | +3.84% |
| 2022-12-31 | $27.94 Million | -15.09% |
| 2021-12-31 | $32.91 Million | -24.06% |
| 2020-12-31 | $43.33 Million | -1.61% |
| 2019-12-31 | $44.04 Million | -14.13% |
| 2018-12-31 | $51.28 Million | +88.08% |
| 2017-12-31 | $27.27 Million | -29.23% |
| 2016-12-31 | $38.53 Million | +6.70% |
| 2015-12-31 | $36.11 Million | +27.60% |
| 2014-12-31 | $28.30 Million | -8.16% |
| 2013-12-31 | $30.82 Million | +150.74% |
| 2012-12-31 | $12.29 Million | +1.91% |
| 2011-12-31 | $12.06 Million | +41.70% |
| 2010-12-31 | $8.51 Million | -49.69% |
| 2009-12-31 | $16.92 Million | -22.96% |
| 2008-12-31 | $21.96 Million | -8.38% |
| 2007-12-31 | $23.96 Million | +19.35% |
| 2006-12-31 | $20.08 Million | -5.16% |
| 2005-12-31 | $21.17 Million | +27.99% |
| 2004-12-31 | $16.54 Million | +96.62% |
| 2003-12-31 | $8.41 Million | +33.50% |
| 2002-12-31 | $6.30 Million | +158.03% |
| 2001-12-31 | $2.44 Million | -25.57% |
| 2000-12-31 | $3.28 Million | +115.29% |
| 1999-12-31 | $1.52 Million | +38.55% |
| 1998-12-31 | $1.10 Million | +22.22% |
| 1997-12-31 | $900.00K | +200.00% |
| 1996-12-31 | $300.00K | -25.00% |
| 1995-12-31 | $400.00K | -- |
About Windtree Therapeutics Inc
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 sur… Read more